De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Agenus Beheer
Beheer criteriumcontroles 2/4
De CEO Agenus' is Garo Armen, benoemd in Jan1994, heeft een ambtstermijn van 30.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.86M, bestaande uit 12.1% salaris en 87.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.7% van de aandelen van het bedrijf, ter waarde $ 832.25K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 4 jaar.
Belangrijke informatie
Garo Armen
Algemeen directeur
US$5.9m
Totale compensatie
| Percentage CEO-salaris | 12.1% |
| Dienstverband CEO | 30.8yrs |
| Eigendom CEO | 0.7% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 4yrs |
Recente managementupdates
Recent updates
Agenus: Novel Drugs That Just Are Not Novel
Jul 24There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
May 21
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
May 09Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet
Mar 29Agenus: 2024 May Finally Be The Year For A Major Turnaround
Jan 18Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Dec 22News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Nov 09A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)
Oct 04Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts
May 10VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma
Oct 12Agenus New Trials Set It Up For The Long Haul
Sep 27Agenus: It's Always Tomorrow
Sep 16Agenus GAAP EPS of -$0.17, revenue of $20.93M
Aug 09Agenus: Successfully Pulled Itself Away From Disaster
Jul 04Agenus: Not Quite Enough
Apr 19Auditors Have Doubts About Agenus (NASDAQ:AGEN)
Mar 06Agenus: Making Another Effort With The FDA
Jan 25Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains
Aug 25Agenus Multiple Value-Adding Events Ahead
Aug 18Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts
Aug 11Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$224m |
| Mar 31 2024 | n/a | n/a | -US$240m |
| Dec 31 2023 | US$6m | US$710k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$271m |
| Jun 30 2023 | n/a | n/a | -US$263m |
| Mar 31 2023 | n/a | n/a | -US$240m |
| Dec 31 2022 | US$6m | US$689k | -US$220m |
| Sep 30 2022 | n/a | n/a | -US$215m |
| Jun 30 2022 | n/a | n/a | US$18m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$10m | US$655k | -US$24m |
| Sep 30 2021 | n/a | n/a | US$4m |
| Jun 30 2021 | n/a | n/a | -US$226m |
| Mar 31 2021 | n/a | n/a | -US$190m |
| Dec 31 2020 | US$6m | US$677k | -US$181m |
| Sep 30 2020 | n/a | n/a | -US$174m |
| Jun 30 2020 | n/a | n/a | -US$168m |
| Mar 31 2020 | n/a | n/a | -US$171m |
| Dec 31 2019 | US$10m | US$634k | -US$108m |
| Sep 30 2019 | n/a | n/a | -US$126m |
| Jun 30 2019 | n/a | n/a | -US$113m |
| Mar 31 2019 | n/a | n/a | -US$87m |
| Dec 31 2018 | US$3m | US$610k | -US$160m |
| Sep 30 2018 | n/a | n/a | -US$147m |
| Jun 30 2018 | n/a | n/a | -US$151m |
| Mar 31 2018 | n/a | n/a | -US$158m |
| Dec 31 2017 | US$4m | US$593k | -US$121m |
Compensatie versus markt: De totale vergoeding ($USD 5.86M ) Garo } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).
Compensatie versus inkomsten: De vergoeding van Garo is gestegen terwijl het bedrijf verliesgevend is.
CEO
Garo Armen (71 yo)
30.8yrs
Tenure
US$5,856,319
Compensatie
Dr. Garo H. Armen, Ph.D. founded Agenus Inc. in 1994 and has been Chief Executive Officer since 1994. He serves as an Executive Chairman at MiNK Therapeutics, Inc. Dr. Armen serves as an Executive Chairman...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 30.8yrs | US$5.86m | 0.70% $ 706.2k | |
| VP of Finance | 18yrs | US$712.75k | 0.036% $ 35.8k | |
| Chief Medical Officer | 3.8yrs | US$1.44m | 0.063% $ 63.3k | |
| Chief Information Officer | 2.8yrs | geen gegevens | geen gegevens | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief People Officer | 2.8yrs | geen gegevens | geen gegevens | |
| Chief Manufacturing Officer | no data | geen gegevens | geen gegevens | |
| Chief Quality Officer | 2.8yrs | geen gegevens | geen gegevens | |
| Member of Advisory Board & Chief Strategic Advisor | less than a year | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Chief Medical Affairs Officer | less than a year | geen gegevens | geen gegevens | |
| Director and President & CEO of MiNK Therapeutics | 2.8yrs | US$7.42m | 0.063% $ 63.6k |
2.8yrs
Gemiddelde duur
60.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 25.8yrs | US$5.86m | 0.70% $ 706.2k | |
| Member of Advisory Board & Chief Strategic Advisor | 1.8yrs | geen gegevens | geen gegevens | |
| Director and President & CEO of MiNK Therapeutics | less than a year | US$7.42m | 0.063% $ 63.6k | |
| Member of Advisory Board | 1.8yrs | US$1.04m | geen gegevens | |
| Independent Director | 8.4yrs | US$366.39k | 0.029% $ 28.8k | |
| Independent Lead Director | 17.8yrs | US$385.50k | 0.013% $ 12.9k | |
| Member of Advisory Board | 1.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 17.6yrs | US$888.14k | 0.021% $ 21.4k | |
| Independent Director | 4yrs | US$242.00k | 0.028% $ 27.6k |
4.0yrs
Gemiddelde duur
68.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).